Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer
2005

Mutation Analysis in Familial Breast Cancer

Sample size: 267 publication Evidence: low

Author Information

Author(s): Lewis Aaron G, Flanagan James, Marsh Anna, Pupo Gulietta M, Mann Graham, Spurdle Amanda B, Lindeman Geoffrey J, Visvader Jane E, Brown Melissa A, Chenevix-Trench Georgia

Primary Institution: Queensland Institute of Medical Research

Hypothesis

Germline mutations in FANCD2, BRIP1/BACH1, LMO4 and SFN may account for some of the unexplained multiple-case breast cancer families.

Conclusion

There is no evidence that highly penetrant exonic or splice site mutations in FANCD2, BRIP1/BACH1, LMO4 or SFN contribute to familial breast cancer.

Supporting Evidence

  • The study identified several variants in the FANCD2 gene but found no evidence of pathogenicity.
  • No highly penetrant mutations were found in BRIP1/BACH1, LMO4, or SFN.
  • The research suggests that other breast cancer susceptibility genes may exist beyond those studied.

Takeaway

The study looked for mutations in certain genes to see if they cause breast cancer in families, but didn't find any strong evidence that they do.

Methodology

The study screened multiple-case breast cancer families for mutations in the genes FANCD2, BRIP1/BACH1, LMO4, and SFN using denaturing high performance liquid chromatography (DHPLC) and sequencing.

Limitations

The study may not have captured all potential mutations due to the focus on specific genes and the screening methods used.

Participant Demographics

Families ascertained through the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Digital Object Identifier (DOI)

10.1186/bcr1336

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication